BTIG Maintains Buy on Neuronetics, Raises Price Target to $6
BTIG analyst Sam Eiber maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $6.
Read original at benzingaStocks · News reference
8-K filing — Neuronetics, Inc. (STIM)
Filed: 2026-08-17 AccNo: 0001193125-26-354051 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 17, 2026, 8:10 PM
- Checked
- Aug 17, 2026, 8:10 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings
Read original at benzingaNeuronetics shares are trading higher after the company reported better-than-expected Q2 financial results.
Read original at benzinga